Evan J. Lipson, M.D., is a medical oncologist at the Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital, as well as an assistant professor of oncology at Johns Hopkins University School of Medicine. Dr. Lipson established the Johns Hopkins Melanoma Program at Sibley in 2012 and opened the program's first clinical trial in the Washington, D.C. region in 2015. He is board certified in internal medicine and medical oncology.
Dr. Lipson has an expertise in melanoma and treatment of patients with cutaneous malignancies, specifically regarding the use of novel immunotherapies.
Dr. Lipson earned his undergraduate degree from the University of Maryland and his medical degree from Mount Sinai School of Medicine. He completed a residency in internal medicine at Johns Hopkins University School of Medicine, as well as a fellowship in medical oncology.
Dr. Lipson is the founder of SeizeTheDays.org, a non-profit organization that chronicles the stories of cancer patients who find interesting and meaningful ways to add life to their days. He is a member of The Johns Hopkins Hospital Multidisciplinary Cancer Committee, as well as the American Society for Clinical Oncology (ASCO), the Society for Melanoma Research, the Society for Immunotherapy of Cancer and the Eastern Cooperative Oncology Group.
Dr. Lipson is a nationally-recognized educator and lecturer about the clinical use of cancer immunotherapy, specifically regarding the management of immune-mediated drug toxicities, often in organ transplant recipients.
Dr. Lipson has contributed to numerous clinical trials, publications and presentations. His research focuses on investigating new therapies for patients with various stages of melanoma, ranging from preventing disease recurrence in high-risk patients to developing innovative drug therapies for patients with advanced disease. Dr. Lipson works to optimize combinations of immune-based therapies, such as cancer vaccines and immune checkpoint inhibitors, in order to achieve maximal anti-tumor activity. As a part of the Johns Hopkins Melanoma and Cancer Immunotherapy programs, Dr. Lipson also collaborates with basic and translational scientists in order to investigate biomarkers of drug efficacy. He is a peer reviewer for The Journal of the National Comprehensive Cancer Network, the ASCO Educational Book Expert Panel, the Journal for Immunotherapy of Cancer, Cancer Management and Research, Cancer Discovery, and Clinical Cancer Research.